title: Effects of chronic administration of doxorubicin on myocardial creatine phosphokinase and antioxidant defenses and levels of lipid peroxidation in tissues and plasma of rats.
abstract: Tissue and plasma levels of thiobarbituric acid reactive substances (TBARS) were measured in rats treated chronically with doxorubicin. In addition, heart creatine phosphokinase and antioxidant defenses were examined. Male rats received doxorubicin (DXR) 2 mg/kg or vehicle weekly subcutaneously for 13 weeks and were sacrificed at 14 and 19 weeks, 1 and 6 weeks after the last dose, respectively. Histological evaluation in DXR-treated rats at 14 and 19 weeks found significant and progressive cardiac and renal lesions as compared to controls. Heart TBARS were unchanged from controls. Plasma and kidney levels of TBARS were elevated above controls at both 14 and 19 weeks. Lung levels of TBARS were significantly elevated above controls at 14 weeks. Liver levels of TBARS were elevated at 19 weeks. Heart creatine phosphokinase activity was significantly depressed from controls at both 14 and 19 weeks. Heart glutathione peroxidase and superoxide dismutase activities were unchanged from controls. Heart glutathione, glutathione reductase, glucose-6-phosphate dehydrogenase, and catalase were elevated above controls at both 14 and 19 weeks. The lack of change in heart TBARS suggests that changes in TBARS in other organs may be secondary processes. The depression of creatine phosphokinase suggests that levels of adenosine triphosphate may be insufficient to sustain the myocardial function and this may partly be responsible for DXR-induced cardiac myopathy.
authors.affiliation: Department of Veterinary Pharmacology, School of Veterinary Medicine, University of California, Davis 95616.
authors.forename: T W
authors.initials: TW
authors.lastname: Robison
authors.forename: S N
authors.initials: SN
authors.lastname: Giri
authors.forename: D W
authors.initials: DW
authors.lastname: Wilson
mesh_terms: D000818:Animals; D002374:Catalase / Q000378:metabolism; D003402:Creatine Kinase / Q000378:metabolism*; D004317:Doxorubicin / Q000494:pharmacology*; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005980:Glutathione Reductase / Q000378:metabolism; D006321:Heart / Q000187:drug effects / Q000502:physiology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D009206:Myocardium / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D013482:Superoxide Dismutase / Q000378:metabolism; D013858:Thiobarbiturates / Q000378:metabolism
chemical_list: D013858:Thiobarbiturates; D004317:Doxorubicin; D005954:Glucosephosphate Dehydrogenase; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D003402:Creatine Kinase; D005978:Glutathione